Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer

Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer

BackgroundPucotenlimab, also called HX008, is a humanized anti-PD-1 antagonist IgG4 mAb. It blocks programmed cell death protein 1 (PD-1), programmed-death ligand 1 (PD-L1), and programmed death ligand-2 (PD-L2). In the CBCSG 006 trial, gemcitabine plus cisplatin (GP) has shown impressive antitumor...

Full description

Bibliographic Details
Main Authors: Jun Cao, Biyun Wang, Jian Zhang, Zhonghua Tao, Leiping Wang, Xichun Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
immunotherapy
pucotenlimab
gemcitabine
cisplatin
metastatic triple-negative breast cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.837963/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.837963/full

Similar Items